疾病治疗药物开发商One Biosciences宣布获得1500万欧元A轮融资，用于推进临床单细胞分析技术-动脉网

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

CISION 等信源发布 2025-07-17 14:30



可切换为仅中文







Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials

资金将用于建立OneMap™的临床实用性，这是一个专有的由人工智能（AI）驱动的单细胞转录组肿瘤学平台，用于指导治疗决策、患者选择、疗法开发并优化临床试验。

Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies

收益还将有助于扩大与制药和生物技术公司的战略合作伙伴关系。

Financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures

由Redmile Group和Blast领投融资，Galion.exe、Invus、Adamed Technology、Sofinnova Partners、Polytechnique Ventures和Kima Ventures参与。

PARIS

巴黎

，

July 17, 2025

2025年7月17日

/PRNewswire/ -- One Biosciences ('One Biosciences' or the 'Company'), a precision oncology techbio company pioneering clinical grade single-cell tumor transcriptomic profiling, today announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.

/PRNewswire/ -- 精准肿瘤学技术公司One Biosciences（“One Biosciences”或“公司”），致力于开创临床级单细胞肿瘤转录组分析，今日宣布完成由Redmile Group和Blast领投的1500万欧元A轮融资，Galion.exe、Invus、Adamed Technology、Sofinnova Partners、Polytechnique Ventures和Kima Ventures等机构参与跟投。

This round brings One Biosciences' total funding, to date, to over €20 million including Home Biosciences' seed financing..

本轮融资使One Biosciences迄今为止的总融资额超过2000万欧元，其中包括Home Biosciences的种子轮融资。

One Biosciences technology creates detailed functional profiles of patient tumors, unlocking insights that may drive better clinical decision-making, patient selection, therapy development, and potentially optimizing clinical trials. Proceeds from the financing will accelerate the clinical development of One Biosciences' flagship OneMap™ platform and support the scaling of strategic partnerships with pharmaceutical and biotech companies..

一家生物科学公司的技术创建了患者肿瘤的详细功能图谱，揭示了可能推动更好的临床决策、患者选择、治疗开发的见解，并有可能优化临床试验。融资所得将加速One Biosciences旗舰平台OneMap™的临床开发，并支持与制药和生物技术公司战略合作伙伴关系的扩展。

Hedi Ben Brahim

赫迪·本·布拉欣

, CEO of One Biosciences, said:

One Biosciences首席执行官表示：

'This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market.'.

“这笔资金使我们能够将突破性的单细胞技术转化为实时洞察，可以直接为医生决策提供信息、改善患者护理并加速药物开发。我们从这群全球领先投资者那里获得的非凡支持，进一步坚定了我们的信念，并加快了我们进入市场的步伐。”

Dr. Céline Vallot, Co-Founder of One Biosciences and group leader at Curie Institute,

塞琳·瓦洛博士，One Biosciences联合创始人及居里研究所团队负责人，

commented

已评论

: 'This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical grade specimens.'

“这项投资加上我们利用专有的单细胞患者数据集训练人工智能算法的成熟能力，将进一步证实我们从临床级样本中预测对大多数肿瘤治疗药物反应的能力。”

博士

Mehdi Touat

梅赫迪·图阿特

, Assistant Professor, Assistance Publique - Hôpitaux de Paris AP-HP, Pitié-Salpêtrière and Paris Brain Institute,

，助理教授，巴黎公立医院集团 (AP-HP)，皮提耶-萨勒佩特里埃医院和巴黎脑科学研究所，

said

说

：

'Widespread use of next generation sequencing (NGS) profiling has led to substantial advances in cancer care but the clinical benefit remains limited to small patient subsets. We believe clinical grade single cell profiling has the potential to catalyze the next generation of diagnostic and therapeutic advances '.

“下一代测序（NGS）技术的广泛应用带来了癌症治疗领域的显著进步，但其临床受益人群仍然局限于小部分患者。我们认为，临床级别的单细胞分析有潜力推动下一代诊断和治疗的进步。”

。

About One Biosciences

关于一生物科学

One Biosciences, founded by Dr. Céline Vallot, Curie Institute and Home Biosciences in 2020, is an AI driven single cell transcriptomic oncology solutions company that is pioneering clinical grade single-cell tumor transcriptomic profiling. We aim to help clinicians select optimal treatments for their patients by decoding tumor heterogeneity from standard clinical samples, while enabling pharmaceutical companies to improve clinical trial outcomes.

One Biosciences 由 Céline Vallot 博士、居里研究所和 Home Biosciences 于2020年创立，是一家以人工智能驱动的单细胞转录组肿瘤学解决方案公司，致力于开创临床级别的单细胞肿瘤转录组分析。我们旨在通过解码来自标准临床样本的肿瘤异质性，帮助临床医生为患者选择最佳治疗方案，同时助力制药公司改善临床试验结果。

One Biosciences has partnerships with Curie Institute, Gustave Roussy Institute and AP-HP and is supported by Medicen, PSCC and Matwin. The company is financed by Bpifrance, Région Ile de France, France 2030, Redmile Group Blast, Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures..

One Biosciences与居里研究所、古斯塔夫·鲁西研究所和巴黎公立医院集团（AP-HP）建立了合作伙伴关系，并得到了Medicen、PSCC和Matwin的支持。公司由法国公共投资银行（Bpifrance）、法兰西岛大区、法国2030计划、Redmile Group Blast、Galion.exe、Invus、Adamed Technology、Sofinnova Partners、Polytechnique Ventures和Kima Ventures提供资金支持。

For more information, visit:

欲了解更多信息，请访问：

www.onebiosciences.fr

SOURCE One Biosciences

源壹生物科学

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &